← Back to headlines
Johnson & Johnson Acquires Option for Sail in vivo CAR-T Therapies
Johnson & Johnson has secured a $2.58 billion option to acquire Sail's in vivo CAR-T therapies. This strategic move aims to bolster Johnson & Johnson's presence in the rapidly evolving field of cell-based cancer treatments.
29 Jul, 21:49 — 29 Jul, 21:49
Sources
Showing 1 of 1 sources
Related Stories
HDFC Bank CEO Sashidhar Jagdishan to Step Down in October
2h ago
FSSAI Bans Everest and Laljee Godhoo From Selling Substandard Hing Powder
3h ago
UAE Central Bank Launches Probe Into Banque Misr Over US Money Laundering Warnings
3h ago
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
4h ago